• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)

Dictionary: Patient Representatives participate in advisory committee meetings to ensure patient input on important medical product review and policy questions.

The Patient Representative’s role is to provide the advisory committee and FDA insight on issues, problems, and/or questions pertinent to the unique viewpoint of patients living with a specific disease.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetPercent
Oct 20098083
Nov 20098063
Dec 20098070
Jan 201080100
Feb 20108067
Mar 20108060
Apr 201080100
May 201080100
Jun 20108050
Jul 20108088
Aug 201080100
Sep 201080100

FY 2010 Overall: 73%

Footnotes

  • (1) This measure will no longer be tracked after April 2012.

Number of FDA advisory committee meetings during the month that had a Patient Representative (1)

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/A5
Nov 2009N/A5
Dec 2009N/A7
Jan 2010N/A2
Feb 2010N/A2
Mar 2010N/A6
Apr 2010N/A3
May 2010N/A4
Jun 2010N/A3
Jul 2010N/A7
Aug 2010N/A4
Sep 2010N/A6

FY 2010 Total: 64

Number of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/A6
Nov 2009N/A8
Dec 2009N/A10
Jan 2010N/A2
Feb 2010N/A3
Mar 2010N/A10
Apr 2010N/A3
May 2010N/A4
Jun 2010N/A6
Jul 2010N/A8
Aug 2010N/A4
Sep 2010N/A6

FY 2010 Total: 88

Total number of advisory committee meetings during the month (1)

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A8
Nov 2009N/A9
Dec 2009N/A12
Jan 2010N/A3
Feb 2010N/A4
Mar 2010N/A11
Apr 2010N/A6
May 2010N/A5
Jun 2010N/A7
Jul 2010N/A11
Aug 2010N/A5
Sep 2010N/A8

FY 2010 Total: 89

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.